Klein Arnold W, Carruthers Alastair, Fagien Steven, Lowe Nicholas J
Los Angeles, Calif.; Boca Raton, Fla.; and Vancouver, British Columbia, Canada From the David Geffen School of Medicine, University of California, Los Angeles, and the Department of Dermatology, University of British Columbia.
Plast Reconstr Surg. 2008 Jun;121(6):413e-422e. doi: 10.1097/PRS.0b013e318170813c.
Botulinum neurotoxin treatment is the most common aesthetic procedure in the United States. A number of serotypes and formulations are available worldwide. Similarities and differences among these toxins were evaluated by reviewing the existing literature.
Reports of botulinum neurotoxin for aesthetic use, published in peer-reviewed literature or presented at recent professional congresses, were reviewed to summarize key features of different toxins. Data from therapeutic uses in comparable anatomical areas were included in the review when aesthetic literature was limited.
Serotypes of neurotoxins share molecular structures and mechanisms of action but exhibit important differences between serotypes and between different formulations within the same serotype, including differences in distribution/diffusion patterns and risk/benefit profiles. The differences attributable to dissimilarities in bacterial strains, manufacturing techniques, and assays are likely to influence clinical performance.
Injection patterns, techniques, dilutions diffusion, and injection volumes established for a specific formulation of botulinum neurotoxin are not likely to be applicable to other formulations, and formulations are not interchangeable by any single conversion ratio. A large proportion of the clinical literature documents the aesthetic uses of the Allergan formulation of botulinum toxin type A. Additional studies are needed to establish optimal procedures for the Ipsen formulation and botulinum neurotoxin, and for diverse aesthetic uses.
肉毒杆菌神经毒素治疗是美国最常见的美容手术。全球有多种血清型和制剂可供使用。通过回顾现有文献评估了这些毒素之间的异同。
对发表在同行评审文献中或在近期专业大会上发表的肉毒杆菌神经毒素美容用途的报告进行回顾,以总结不同毒素的关键特征。当美容文献有限时,来自可比解剖区域治疗用途的数据也纳入了回顾。
神经毒素的血清型具有共同的分子结构和作用机制,但不同血清型之间以及同一血清型内不同制剂之间存在重要差异,包括分布/扩散模式和风险/效益概况的差异。细菌菌株、生产技术和检测方法的不同所导致的差异可能会影响临床效果。
为特定肉毒杆菌神经毒素制剂确定的注射模式、技术、稀释度、扩散和注射量不太可能适用于其他制剂,且制剂不能通过任何单一换算比例相互替换。大部分临床文献记录了艾尔建公司A型肉毒杆菌毒素制剂的美容用途。需要进一步研究来确定益普生公司制剂和肉毒杆菌神经毒素的最佳程序,以及用于各种美容用途的最佳程序。